3.15
-0.26 (-7.62%)
Penutupan Terdahulu | 3.41 |
Buka | 3.45 |
Jumlah Dagangan | 120,657 |
Purata Dagangan (3B) | 58,616 |
Modal Pasaran | 47,127,468 |
Harga / Jualan (P/S) | 1.19 |
Harga / Buku (P/B) | 1.78 |
Julat 52 Minggu | |
Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
Margin Keuntungan | -7.98% |
Margin Operasi (TTM) | 11.03% |
EPS Cair (TTM) | -0.240 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 37.80% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 36.84% |
Nisbah Semasa (MRQ) | 1.25 |
Aliran Tunai Operasi (OCF TTM) | 5.42 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 3.56 M |
Pulangan Atas Aset (ROA TTM) | -2.70% |
Pulangan Atas Ekuiti (ROE TTM) | -11.86% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
Stok | Cumberland Pharmaceuticals Inc. | - | - |
AISkor Stockmoo
Konsensus Penganalisis | 0.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -1.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | -2.0 |
Purata | -0.75 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ. |
|
Sektor | Healthcare |
Industri | Drug Manufacturers - Specialty & Generic |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 41.54% |
% Dimiliki oleh Institusi | 28.76% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Berkshire Asset Management Llc/Pa | 31 Mar 2025 | 153,810 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
23 Jun 2025 | Pengumuman | Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference |
27 May 2025 | Pengumuman | NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS |
13 May 2025 | Pengumuman | CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH |
06 May 2025 | Pengumuman | Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 |
29 Apr 2025 | Pengumuman | CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |